Beam Therapeutics Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029: Christi Shaw

Beam Therapeutics Inc.’s own tally for this item (“Elect Director: Christi Shaw”): 65,652,959 for, 6,893,102 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – The following nominees were elected as Class III directors to serve on the Company's board of directors until the Company's 2029 annual meeting of stockholders, and until his or her successor has been duly elected and qualified, based on the following votes:”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 32,535,732 for, 906,587 against, 29,911 abstained.

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

Description as filed by funds: Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029: John Evans

Beam Therapeutics Inc.’s own tally for this item (“Elect Director: John Evans”): 71,684,417 for, 864,042 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – The following nominees were elected as Class III directors to serve on the Company's board of directors until the Company's 2029 annual meeting of stockholders, and until his or her successor has been duly elected and qualified, based on the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 33,233,427 for, 208,890 against, 29,911 abstained.

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

Description as filed by funds: Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029: John Maraganore, Ph.D.

Beam Therapeutics Inc.’s own tally for this item (“Elect Director: John Maraganore, Ph.D.”): 64,846,080 for, 7,701,591 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – The following nominees were elected as Class III directors to serve on the Company's board of directors until the Company's 2029 annual meeting of stockholders, and until his or her successor has been duly elected and qualified, based on the following votes:”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 32,468,968 for, 973,349 against, 29,911 abstained.

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers.

Beam Therapeutics Inc.’s own tally for this item (“3. Compensation of the Company's named executive officers”): 71,546,749 for, 985,066 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – The compensation of the Company's named executive officers was approved, on an advisory basis, based on the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 65 managers: 33,265,328 for, 176,781 against, 29,911 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 235 managers: 41,564,195 for, 607,166 against, 1,570,747 withheld, 3,694 abstained, 39 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2026.

Beam Therapeutics Inc.’s own tally for this item (“2. Appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2026”): 85,754,272 for, 165,746 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2026 was ratified, based on the following votes:”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 33,441,548 for, 770 against, 29,911 abstained.

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.